RPL34

Across TCGA pan-cancer cohorts, RPL34 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL34 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL34 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL34 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and GBM are the cancer types where RPL34 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.799	0.364	.005	11	view →
UCEC	DFS	Quartile	II,III,IV	0.903	0.429	.023	8	view →
GBM	OS	Tertile	All	0.626	0.280	.007	7	view →
HNSC	DFS	Quartile	III,IV	0.669	0.929	.020	3	view →
LSCC	OS	Quartile	All	0.968	0.741	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL34–LUAD (DFS)

Open the LUAD breakdown →